Literature DB >> 16829915

VEGF inhibitors make blood.

Christian Fischer, Peter Carmeliet, Edward M Conway.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16829915     DOI: 10.1038/nm0706-732

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  5 in total

Review 1.  Recombinant adenovirus as a methodology for exploration of physiologic functions of growth factor pathways.

Authors:  Kevin Wei; Frank Kuhnert; Calvin J Kuo
Journal:  J Mol Med (Berl)       Date:  2007-09-22       Impact factor: 4.599

2.  Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.

Authors:  Andrew X Zhu; Dan G Duda; Marek Ancukiewicz; Emmanuelle di Tomaso; Jeffrey W Clark; Rebecca Miksad; Charles S Fuchs; David P Ryan; Rakesh K Jain
Journal:  Clin Cancer Res       Date:  2010-09-15       Impact factor: 12.531

3.  ATF4 plays a pivotal role in the development of functional hematopoietic stem cells in mouse fetal liver.

Authors:  Yunze Zhao; Jie Zhou; Dan Liu; Fang Dong; Hui Cheng; Weili Wang; Yakun Pang; Yajie Wang; Xiaohuan Mu; Yanli Ni; Zhuan Li; Huiyu Xu; Sha Hao; Xiaochen Wang; Shihui Ma; Qian-fei Wang; Guozhi Xiao; Weiping Yuan; Bing Liu; Tao Cheng
Journal:  Blood       Date:  2015-09-17       Impact factor: 22.113

4.  H-ras regulates angiogenesis and vascular permeability by activation of distinct downstream effectors.

Authors:  Doinita Serban; Jie Leng; David Cheresh
Journal:  Circ Res       Date:  2008-05-08       Impact factor: 17.367

5.  Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.

Authors:  Wei Tian; Wenping Ding; Sungkyoung Kim; Leizhen Zheng; Li Zhang; Xiaoping Li; Jianchun Gu; Lian Zhang; Minggui Pan; Siyu Chen
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.